Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19.

Zahra, Fatema Tuz; Bellusci, Lorenza; Grubbs, Gabrielle; Golding, Hana; Khurana, Surender

Zahra, Fatema Tuz; Bellusci, Lorenza; Grubbs, Gabrielle; Golding, Hana; Khurana, Surender.

Zahra FT; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Bellusci L; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Grubbs G; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Golding H; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Khurana S; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, Maryland, USA Surender.Khurana@fda.hhs.gov.

Ann Rheum Dis ; 81(7): 1044-1045, 2022 07.

Article in English | MEDLINE | ID: covidwho-1685513

Subject(s)

COVID-19; SARS-CoV-2; COVID-19/therapy; Humans; Immunization, Passive; Immunoglobulins; COVID-19 Serotherapy

Keywords

Covid-19; autoimmune diseases; biological therapy; therapeutics

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Variants Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2022 Document Type: Article Affiliation country: Annrheumdis-2022-222115

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google